Literature DB >> 12162735

Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes.

Tomas T Ding1, Seung-Jae Lee, Jean-Christophe Rochet, Peter T Lansbury.   

Abstract

The Parkinson's disease substantia nigra is characterized by the loss of dopaminergic neurons and the presence of cytoplasmic fibrillar Lewy bodies in surviving neurons. The major fibrillar protein of Lewy bodies is alpha-synuclein. Two point mutations in the alpha-synuclein gene are associated with autosomal-dominant Parkinson's disease (FPD). Studies of the in vitro fibrillization behavior of the mutant proteins suggest that fibril precursors, or alpha-synuclein protofibrils, rather than the fibrils, may be pathogenic. Atomic force microscopy (AFM) revealed two distinct forms of protofibrillar alpha-synuclein: rapidly formed spherical protofibrils and annular protofibrils, which were produced on prolonged incubation of spheres. The spherical protofibrils bound to brain-derived membrane fractions much more tightly than did monomeric or fibrillar alpha-synuclein, and membrane-associated annular protofibrils were observed. The structural features of alpha-synuclein annular protofibrils are reminiscent of bacterial pore-forming toxins and are consistent with their porelike activity in vitro. Thus, abnormal membrane permeabilization may be a pathogenic mechanism in PD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12162735     DOI: 10.1021/bi020139h

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  121 in total

1.  Effects of curvature and composition on α-synuclein binding to lipid vesicles.

Authors:  Elizabeth R Middleton; Elizabeth Rhoades
Journal:  Biophys J       Date:  2010-10-06       Impact factor: 4.033

Review 2.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

3.  Identification of ciliary neurotrophic factor receptor alpha as a mediator of neurotoxicity induced by alpha-synuclein.

Authors:  Jun Liu; Min Shi; Zhen Hong; JianPeng Zhang; Joshua Bradner; Thomas Quinn; Richard P Beyer; Patrick L Mcgeer; ShengDi Chen; Jing Zhang
Journal:  Proteomics       Date:  2010-06       Impact factor: 3.984

4.  Definition of a molecular pathway mediating α-synuclein neurotoxicity.

Authors:  Jacqueline Burré; Manu Sharma; Thomas C Südhof
Journal:  J Neurosci       Date:  2015-04-01       Impact factor: 6.167

5.  Amyloid ion channels: a common structural link for protein-misfolding disease.

Authors:  Arjan Quist; Ivo Doudevski; Hai Lin; Rushana Azimova; Douglas Ng; Blas Frangione; Bruce Kagan; Jorge Ghiso; Ratnesh Lal
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-14       Impact factor: 11.205

6.  Side-chain interactions determine amyloid formation by model polyglutamine peptides in molecular dynamics simulations.

Authors:  Alexander J Marchut; Carol K Hall
Journal:  Biophys J       Date:  2006-03-24       Impact factor: 4.033

Review 7.  Molecular mechanisms of alpha-synuclein neurodegeneration.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  Biochim Biophys Acta       Date:  2008-10-09

8.  Binding of alpha-synuclein with Fe(III) and with Fe(II) and biological implications of the resultant complexes.

Authors:  Yong Peng; Chengshan Wang; Howard H Xu; You-Nian Liu; Feimeng Zhou
Journal:  J Inorg Biochem       Date:  2009-11-18       Impact factor: 4.155

Review 9.  Exploring the accessible conformations of N-terminal acetylated α-synuclein.

Authors:  Gina M Moriarty; Maria K Janowska; Lijuan Kang; Jean Baum
Journal:  FEBS Lett       Date:  2013-03-13       Impact factor: 4.124

10.  Detecting morphologically distinct oligomeric forms of alpha-synuclein.

Authors:  Sharareh Emadi; Srinath Kasturirangan; Min S Wang; Philip Schulz; Michael R Sierks
Journal:  J Biol Chem       Date:  2009-01-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.